Evaluation of c-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: A cohort analysis from the anglo-scandinavian cardiac outcomes trial lipid-lowering arm

Journal of the American College of Cardiology

Volumn 62, Issue 8, 2013, Pages 717-729

  Sever, Peter S ^a   Poulter, Neil R ^a   Chang, Choon L ^a   Thom, Simon A M ^a   Hughes, Alun D ^a   Welsh, Paul ^b   Sattar, Naveed ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

C reactive protein; cohort; study

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT OUTCOME;

BMI; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASE; CHD; CI; COHORT; CONFIDENCE INTERVAL; CORONARY HEART DISEASE; CRP; CVD; HAZARD RATIO; HDL-C; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; HR; INTERQUARTILE RANGE; IQR; LDL-C; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; MI; MYOCARDIAL INFARCTION; STUDY;

AGED; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PYRROLES; TREATMENT OUTCOME;

EID: 84883342646     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.02.098     Document Type: Article

References (23)

1. M.L. Entman, L. Michael, and R.D. Rossen Inflammation in the course of early myocardial ischemia FASEB J 5 1991 2529 2537
2. P. Libby, P.M. Ridker, and A. Maseri Inflammation and atherosclerosis Circulation 105 2002 1135 1143
3. J.P. Casas, T. Shah, A.D. Hingorani, J. Danesh, and M.B. Pepys C-reactive protein and coronary heart disease: a critical review J Intern Med 264 2008 295 314
4. P.K. Shah Inflammation and plaque vulnerability Cardiovasc Drugs Ther 23 2009 31 40
5. G.D.O. Lowe, and M.B. Pepys C-reactive protein and cardiovascular disease: weighing the evidence Curr Atheroscler Rep 8 2006 421 428
6. The Emerging Risk Factors Collaboration C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis Lancet 375 2010 132 140
7. P.M. Ridker C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus J Am Coll Cardiol 49 2007 2129 2138
8. S. Deveraj, U. Singh, and I. Jialal The evolving role of C-reactive protein in atherothrombosis Clin Chem 55 2009 229 238
9. The Emerging Risk Factors Collaboration C-reactive protein, fibrinogen, and cardiovascular disease prediction N Engl J Med 367 2012 1310 1320
10. J.-P. Després CRP: star trekking the galaxy of risk markers Lancet 377 2011 441 442
11. E. Braunwald Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE-IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials Eur Heart J 33 2012 430 432
12. P.S. Sever, N.R. Poulter, and C.L. Chang Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial Eur Heart J 33 2012 486 494
13. P.S. Sever, B. Dahlöf, N.R. Poulter for the ASCOT Investigators Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators J Hypertens 6 2001 1139 1147
14. P.S. Sever, B. Dahlof, N.R. Poulter for the ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid-Lowering Arm (ASCOT-LLA) Lancet 361 2003 1149 1158
15. B. Dahlof, P.S. Sever, N.R. Poulter for the ASCOT Investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) Lancet 366 2005 895 906
16. D.B. Rubin Inference and missing data Biometrika 63 1976 581 592
17. Heart Protection Study Collaborative Group C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20536 patients in the Heart Protection Study Lancet 377 2011 469 476
18. N. Sattar, H.M. Murray, A. McConnachie for the PROSPER Study Group C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Circulation 115 2007 981 989
19. P.M. Ridker, E. Danielson, F.A.H. Fonseca for the JUPITER Trial Study Group Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 2009 1175 1182
20. P.M. Ridker, C.P. Cannon, D. Morrow for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
21. D.A. Morrow, J.A. de Lemos, and M.S. Sabatine Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial Circulation 114 2006 281 288
22. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen for the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators Statin therapy, LDL cholesterol, C-reactive protein and coronary artery disease N Engl J Med 352 2005 29 38
23. B.J. Arsenault, P. Barter, and D.A. DeMicco Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and non-lipid biomarkers J Am Coll Cardiol 57 2011 63 69